Cargando…
Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials
Autores principales: | Schulz, Martin, Bashirians, George, Cheng, Seng H., Levy, Daniel I., Lundie, Mark, Wilcox, Lisa, Winburn, Ian, Somanathan, Suryanarayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585313/ https://www.ncbi.nlm.nih.gov/pubmed/37868207 http://dx.doi.org/10.1016/j.omtm.2023.101119 |
Ejemplares similares
-
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
por: Okada, Hironori, et al.
Publicado: (2013) -
rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
por: Ishii, Akiko, et al.
Publicado: (2020) -
Durability of transgene expression after rAAV gene therapy
por: Muhuri, Manish, et al.
Publicado: (2022) -
Transduction catalysis: Doxorubicin amplifies rAAV-mediated gene expression in the cortex of higher-order vertebrates
por: Gong, Hongliang, et al.
Publicado: (2021) -
A comparison of the impact on neuronal transcriptome and cognition of rAAV5 transduction with three different doses in the mouse hippocampus
por: Liu, Yi-Si, et al.
Publicado: (2023)